GUOTAI HAITONG SECURITIES·2026-03-12 05:45Investment Rating - The report assigns an "Accumulate" rating to Rongchang Biopharma with a target price of 143.89 RMB [4]. Core Insights - The report predicts that Rongchang Biopharma will enter a new growth phase starting in 2026, driven by the launch of new indications for RC18, RC48, and RC28, which are expected to enter the medical insurance coverage [11][15]. - The company is expected to achieve revenue of 32.51 billion RMB in 2025, 78.32 billion RMB in 2026, and 62.79 billion RMB in 2027, with a significant increase in net profit anticipated in 2026 [3][11]. Financial Summary - Total revenue is projected to grow from 1,083 million RMB in 2023 to 7,832 million RMB in 2026, reflecting a growth rate of 140.9% [3]. - Net profit (attributable to the parent company) is expected to turn positive in 2025 with a forecast of 644 million RMB, and further increase to 5,031 million RMB in 2026 [3]. - Earnings per share (EPS) is projected to rise from -2.68 RMB in 2023 to 8.91 RMB in 2026 [3]. Revenue Growth Drivers - The anticipated growth is attributed to the approval and market entry of new indications for RC48 and RC18, as well as the expected launch of RC28 [15][21]. - RC48 is set to be approved for first-line treatment of UC and HER2 low-expressing breast cancer, which will significantly expand its market potential [16][21]. - RC18 is expected to see increased volume as it enters medical insurance coverage for multiple indications, including MG and IgAN [21][25]. Strategic Partnerships - The company has entered into several strategic partnerships, including the licensing of RC148 to AbbVie, which is expected to enhance its global competitive position in oncology [34][36]. - The partnership with Santen Pharmaceutical for RC28 is also expected to maximize its market potential in the ophthalmic sector [30]. Clinical Development Pipeline - The report highlights the ongoing clinical trials for RC148, which show promising efficacy in treating various cancers, including NSCLC [36][38]. - RC18 is advancing in global clinical trials, with significant potential for treating MG and other autoimmune diseases [25][26]. Market Positioning - Rongchang Biopharma is positioned to leverage its innovative drug pipeline and strategic partnerships to capture significant market share in the oncology and autoimmune sectors [11][34].